Investors aiming for above-average returns often turn to the practice of stock picking. Skillful choices in individual stocks can be a catalyst for substantial wealth growth.
After finishing at $20.29 in the prior trading day, Arcus Biosciences Inc (NYSE: RCUS) closed at $20.19, down -0.49%. In other words, the price has decreased by -$0.49 from its previous closing price. On the day, 1.0 million shares were traded. RCUS stock price reached its highest trading level at $20.728 during the session, while it also had its lowest trading level at $19.9232.
Ratios:
Our goal is to gain a better understanding of RCUS by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.65 and its Current Ratio is at 3.65. In the meantime, Its Debt-to-Equity ratio is 0.25 whereas as Long-Term Debt/Eq ratio is at 0.22.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of. The stock’s future direction. In the most recent recommendation for the company, H.C. Wainwright on February 26, 2025, Upgraded its rating to Buy and sets its target price to $24 from $18 previously.
On October 21, 2024, H.C. Wainwright started tracking the stock assigning a Neutral rating and target price of $20.
On October 08, 2024, Wells Fargo started tracking the stock assigning a Overweight rating and target price of $29.Wells Fargo initiated its Overweight rating on October 08, 2024, with a $29 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Oct 30 ’25 when Juan Jaen bought 1,173 shares for $20.19 per share.
Jaen Juan C. sold 77,840 shares of RCUS for $1,626,634 on Oct 29 ’25. The President now owns 1,091,374 shares after completing the transaction at $20.90 per share. On Oct 28 ’25, another insider, Jaen Juan C., who serves as the President of the company, sold 19,019 shares for $20.19 each. As a result, the insider received 383,944 and left with 1,169,214 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RCUS now has a Market Capitalization of 2179985664 and an Enterprise Value of 1480985728. For the stock, the TTM Price-to-Sale (P/S) ratio is 9.08 while its Price-to-Book (P/B) ratio in mrq is 4.96. Its current Enterprise Value per Revenue stands at 6.171 whereas that against EBITDA is -4.057.
Stock Price History:
The Beta on a monthly basis for RCUS is 0.94, which has changed by 0.3025806 over the last 52 weeks, in comparison to a change of 0.19088471 over the same period for the S&P500. Over the past 52 weeks, RCUS has reached a high of $22.11, while it has fallen to a 52-week low of $6.50. The 50-Day Moving Average of the stock is 46.76%, while the 200-Day Moving Average is calculated to be 89.17%.
Shares Statistics:
The stock has traded on average 999.06K shares per day over the past 3-months and 1358880 shares per day over the last 10 days, according to various share statistics. A total of 107.10M shares are outstanding, with a floating share count of 66.27M. Insiders hold about 38.63% of the company’s shares, while institutions hold 62.49% stake in the company. Shares short for RCUS as of 1760486400 were 8653075 with a Short Ratio of 8.66, compared to 1757894400 on 10898426. Therefore, it implies a Short% of Shares Outstanding of 8653075 and a Short% of Float of 12.43.
Earnings Estimates
The stock of Arcus Biosciences Inc (RCUS) is currently being evaluated by 3.0 analysts who are actively contributing to its market rating.The consensus estimate for the next quarter is -$1.07, with high estimates of -$1.07 and low estimates of -$1.07.
Analysts are recommending an EPS of between -$3.65 and -$3.65 for the fiscal current year, implying an average EPS of -$3.65. EPS for the following year is -$4.22, with 4.0 analysts recommending between -$3.54 and -$4.97.
Revenue Estimates
4 analysts predict $18.81M in revenue for. The current quarter. It ranges from a high estimate of $20M to a low estimate of $17.5M. As of. The current estimate, Arcus Biosciences Inc’s year-ago sales were $36MFor the next quarter, 4 analysts are estimating revenue of $40.63M. There is a high estimate of $59.1M for the next quarter, whereas the lowest estimate is $17.8M.
A total of 7 analysts have provided revenue estimates for RCUS’s current fiscal year. The highest revenue estimate was $235.5M, while the lowest revenue estimate was $229M, resulting in an average revenue estimate of $231.43M. In the same quarter a year ago, actual revenue was $258MBased on 8 analysts’ estimates, the company’s revenue will be $137.65M in the next fiscal year. The high estimate is $191.7M and the low estimate is $71M.
